Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia

Simsek, Eda; EŞKAZAN, AHMET; Cengiz, Mahir; AR, Muhlis; EKİZOĞLU ERATAK, Seda; SALİHOĞLU, Ayşe; Gulturk, Emine; ELVERDİ, Tuğrul; Aydin, Seniz; DEMİRÖZ, AHU; BUYRU, Ayşe; BAŞLAR, Zafer; Ozbek, Ugur; Ferhanoglu, Burhan; Aydin, YILDIZ; Tuzuner, Nukhet; SOYSAL, Teoman

doi:10.1136/jclinpath-2015-203320

Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia

Atıf İçin Kopyala

Simsek E. T., EŞKAZAN A. E., Cengiz M., AR M. C., EKİZOĞLU ERATAK S., SALİHOĞLU A., ...Daha Fazla

JOURNAL OF CLINICAL PATHOLOGY, cilt.69, sa.9, ss.810-816, 2016 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 69 Sayı: 9
Basım Tarihi: 2016
Doi Numarası: 10.1136/jclinpath-2015-203320
Dergi Adı: JOURNAL OF CLINICAL PATHOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.810-816
Anahtar Kelimeler: CML, MYELOFIBROS, HEMATOPATHOLOGY, CHRONIC MYELOGENOUS LEUKEMIA, KINASE INHIBITOR STI571, CHRONIC-PHASE, RELEVANCE, THERAPY, RECOMMENDATIONS, DIAGNOSIS
Marmara Üniversitesi Adresli: Evet

Özet

Aims Before the era of tyrosine kinase inhibitors (TKIs), the presence of bone marrow fibrosis (MF) in patients with chronic myeloid leukaemia (CML) has been established as a poor prognostic factor. The aim of the present study was to evaluate the effects of imatinib treatment on MF and the prognostic significance of MF at this new era of CML therapy.